Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== Pediatric Assessment Techniques == In infants and young children, clinical evaluation of skin turgor requires a different approach than in adults due to differences in subcutaneous fat distribution. Medical Professionals perform the pinch test on the child's abdomen or the inner thigh rather than the hand or forearm. A pinch that remains elevated for less than two seconds indicates mild to modern dehydration, while a fold that tents for longer than two seconds signifies severe, life-threatening fluid loss. However, the reliability of this test changes if a child is severely malnourished or obese, as excessive fat can mask poor turgor.
Topical beta-adrenergic receptor antagonists, such as timolol, levobunolol, and betaxolol, decrease aqueous humor production by the epithelium of the ciliary body. Alpha2-adrenergic agonists, such as brimonidine and apraclonidine, work by a dual mechanism, decreasing aqueous humor production and increasing uveoscleral outflow. Less-selective alpha agonists, such as epinephrine, decrease aqueous humor production through vasoconstriction of ciliary body blood vessels, useful only in open-angle glaucoma. Epinephrine's mydriatic effect, however, renders it unsuitable for closed-angle glaucoma due to further narrowing of the uveoscleral outflow (i.e., further closure of the trabecular meshwork, which is responsible for the absorption of aqueous humor). Miotic agents (parasympathomimetics), such as pilocarpine, work by contraction of the ciliary muscle, opening the trabecular meshwork and allowing increased outflow of the aqueous humor. Echothiophate, an acetylcholinesterase inhibitor, is used in chronic glaucoma. Carbonic anhydrase inhibitors, such as dorzolamide, brinzolamide, and acetazolamide, lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body. Each of these medicines may have local and systemic side effects. Wiping the eye with an absorbent pad after the administration of eye drops may result in fewer adverse effects. Initially, glaucoma drops may reasonably be started in either one or in both eyes.
== Signs and symptoms == NL/NLD most frequently appears on the patient's shins, often on both legs, although it may also occur on forearms, hands, trunk, and, rarely, nipple, penis, and surgical sites. The lesions are often asymptomatic, but may become tender and ulcerate when injured. The first symptom of NL is often a "bruised" appearance (erythema) that is not necessarily associated with a known injury. The extent to which NL is inherited is unknown. NLD appears as a hardened, raised area of the skin. The center of the affected area usually has a yellowish tint, while the area surrounding it is a dark pink. The affected area can spread or turn into an open sore. When this happens, the patient is at greater risk of developing ulcers. If an injury to the skin occurs on the affected area, it may not heal properly, or it will leave a dark scar.
== Bibliography == Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Oxford: Butterworth-Heinemann. ISBN 978-0-08-037941-8. Holleman, Arnold F.; Wiberg, Nils (2007). Textbook of Inorganic Chemistry (102nd ed.). Berlin: de Gruyter. ISBN 978-3-11-017770-1. Peterson, J. R.; Hobart, D. E. (1984). "The Chemistry of Berkelium". In Emeléus, Harry Julius (ed.). Advances in inorganic chemistry and radiochemistry. Vol. 28. Academic Press. pp. 29–64. doi:10.1016/S0898-8838(08)60204-4. ISBN 978-0-12-023628-2.
On March 7, 2025, Duterte left for Hong Kong alongside Honeylet Avanceña, his daughter Veronica and his entourage. Although his lawyer Salvador Panelo said that his purpose of travel was to attend a KOJC-organized campaign sortie for Partido Demokratiko Pilipino among overseas Filipino workers, his departure coincided with reports that the release of an arrest warrant for Duterte from the International Criminal Court (ICC) was imminent. Others who attended the event include Duterte's daughter, Vice President Sara Duterte, Senators Ronald dela Rosa and Bong Go, and senatorial candidates Rodante Marcoleta and Vic Rodriguez. On March 11, 2025, upon his return from Hong Kong on a commercial flight, Duterte was arrested at Ninoy Aquino International Airport for crimes against humanity of murder, torture, and rape. The warrant was issued by the ICC, but coursed through Interpol. A top official of the Marcos administration earlier said that the government would honor its commitments to Interpol if an arrest warrant was issued, despite its policy of not cooperating with the ICC. Duterte questioned the warrant's legitimacy, asserting that the arrest did not follow standard procedures and that any prosecution should occur within the Philippines. His supporters rallied in major cities condemning the arrest, while activists hailed the arrest as a pivotal moment for justice. He was soon surrendered to the ICC in The Hague, Netherlands, where he was being held as of 11 March 2025.
Sources: en.wikipedia.org
He later offered to repay the sum, but Political Quarterly, which had paid the prize money, instead invited him to make a donation to English PEN, of which George Orwell had been a member. Hari arranged with English PEN to make a donation equal to the value of the prize, to be paid in installments when he returned to work at The Independent, but he did not return to work there.
A wide range of applications have been demonstrated for AMMs, including those integrated into polymeric, liquid crystal, and crystalline systems for varied functions (such as materials research, homogenous catalysis and surface chemistry).
Despite the fact that the period of the wars of independence itself was marked by a rapid expansion of representative government, for several of the new nations the nineteenth century was marked by militarism because of the lack of well-defined political and national institutions. The armies and officers that came into existence during the process of independence wanted to ensure that they got their rewards once the struggle was over. Many of these armies did not fully disband once the wars were over and they proved to be one of the stabler institutions in the first decades of national existence. These armies and their leaders effectively influenced the course of political development. Out of this new tradition came the caudillos, strongmen who amassed formal and informal economic, military and political power in themselves.
=== Toxicity === Overdose from dietary sources alone is unlikely because excess magnesium in the blood is promptly filtered by the kidneys. Overdose is more likely in the presence of impaired renal function. Overdose is likely in cases of excessive intake of supplements. Megavitamin therapy has caused death in a child, and severe hypermagnesemia in a woman and a young girl who had healthy kidneys. The most common symptoms of overdose are nausea, vomiting, and diarrhea; other symptoms include hypotension, confusion, slowed heart and respiratory rates, deficiencies of other minerals, coma, cardiac arrhythmia, and death from cardiac arrest. Inhalation of magnesium oxide in industrial settings can cause metal fume fever.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.